TheraJan, LLC. produces an experimental canine EGFR/HER2 Peptide Immunotherapeutic. Safety and efficacy have NOT yet been established by the USDA.
For use under supervision/ administration of a licensed veterinary oncologist.
Few new therapies exist for the treatment of dog cancers. Surgery, chemotherapy, and radiation have been utilized for decades to treat a variety of dog cancers. Canine EGFR/HER2 Peptide Cancer Immunotherapeutic is a newly developed vaccination that is reported to stimulate immune responses, antibodies and T cells, specific for tumor surface proteins EGFR/HER2 [see Doyle, et. al., . Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021; PMID: 34419682). So called "lmmunotherapy" has revolutionized the care of human cancers and is now being investigated for safety and efficacy in canine cancer. The immunotherapeutic was developed by investigators at the Yale University School of Medicine.
This is a USDA regulated scientific study with the goal of obtaining approval that will allow greater availability of the vaccine to treat more dogs. Safety and efficacy have not yet been established by the USDA. This study has specific criteria and requirements for enrollment. It is imperative that trial sites adhere to the protocol and obtain the required samples and data.
At this time, the study is open to dogs with confirmed osteosarcoma, hemangiosarcoma, and transitional cell carcinoma.
The vaccine is currently provided to the study sites and owner at no charge. As this is not a fully funded study, all costs associated with evaluation, testing, and vaccine administration are the responsibility of the owner.
